Tags: 
Preliminary data suggest that survivors of SARS-CoV-2 infection may be susceptible to reinfection within weeks or months.
One study in ~1,500 COVID patients show that 10 percent % of these patients had undetectable antibody levels within weeks of first symptoms or lost their antibodies two to three months after recovering from the infection.
Early works showed that most people who become infected with COVID19 produce IgG antibody which even if in small amounts can still neutralize the virus in vitro.
A recent Nature Medicine (https://www.nature.com/articles/s41591-020-0965-6) study, compared antibody formation in 37 asymptomatic and 37 symptomatic COVID 19 subjects. Results showed that the virus-specific IgG levels in the asymptomatic group were significantly lower relative to the symptomatic group. But, 40% of the asymptomatic patients became seronegative with undetectable levels of protective antibodies in the two to three months after the infection compared to 13 percent of the symptomatic patients who became negative for IgG in the early convalescent phase.
These results are interesting but deserve more research in a larger population.
Dr. Anthony Fauci, the director of the National Institute of Allergy and Infectious Diseases, in a conversation (https://www.youtube.com/watch?v=3MH-3ICY-N4&feature=youtu.be) with Howard Bauchner, he said that in addition to a lack of consistency among testing methods, individuals do not have “a uniformly robust antibody response.” This fact may make it difficult to develop a vaccine that works equally well for all people.
We hope that humanity will have vaccines to fight COVID19!!
Here are the variety of technologies adopted for COVID19 vaccine development by dozens of vaccine candidates.
Specializing in rare disease, Boston Biotech Clinical Research works with biotech, pharmaceutical, device companies and investors to streamline the clinical trial process. Our experienced team helps each client reach their specific goals by customizing a clinical and regulatory road map of simplified programs and streamlined protocols to meet our clients’ requirements.